Lupin has received final approval from the US health regulator to market its antibacterial Nitrofurantoin capsules used for treating urinary tract infections.
According to a company statement, Lupin will market the Nitrofurantoin capsules in the strengths of 50 mg and 100 mg. The product is a generic version of Alvogen Malta Operations Ltd’s Macrodantin capsules in the same strengths.
As per IQVIA MAT April 2018 data, Nitrofurantoin capsules USP 50 mg and 100 mg had annual sales of around $27 million in the US.
Lupin shares were trading at Rs 899.15 per scrip on the BSE, down 0.22 per cent from its previous close.